The revision was informed by a variety of data, including insights into Librela's safety profile and a new flow chart projecting the drug's revenue for 2025. InvestingPro reveals that 4 analysts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback